Mr. John Farlinger reports

TELO GENOMICS FILES PATENT TO EXPAND IP PORTFOLIO TO LIQUID BIOPSY MRD APPLICATIONS FOR MULTIPLE MYELOMA

Telo Genomics Corp. has filed a U.S. provisional patent application seeking to protect a new TeloView biomarker algorithm for use with liquid biopsy samples, even those with minimal residual disease, in the management of patients with multiple myeloma.

"This filing reflects our continued focus on building intellectual property around high-value applications of the TeloView platform," said John Farlinger, Telo's chief executive officer. "As MRD becomes increasingly important in multiple myeloma patient assessment and treatment development, we believe there is a significant opportunity to advance blood-based approaches that complement the current clinical practice."

The latest patent application aims to protect a new TeloView algorithm that can predict the risk of relapses in MM patients and the workflow to isolate circulating cancer cells from peripheral blood samples in the MRD setting. This expanded IP portfolio will strengthen Telo's competitive position, support future commercial partnerships and further differentiate TeloView from existing MRD technologies.

TeloView is a proprietary diagnostic platform which analyzes the 3-D telomere and nuclear architecture to assess genomic instability, a fundamental driver of cancer progression. This technology works even at the level of single cell analysis. The platform has generated multiple prognostic algorithms applicable in oncology and neurodegenerative diseases. Telo continues to expand its intellectual property portfolio to protect these clinical applications, with patent coverage for TeloView extending through 2043.

MRD is a Food and Drug Administration-approved clinical end point, and MRD assessment has become an increasingly important component of MM clinical practice, research and drug development. However, currently available MRD technologies primarily measure residual tumour burden and generally require invasive bone marrow samples, limiting their suitability for routine longitudinal monitoring of patients and providing limited insight into the biological status of that residual disease. Telo's peripheral blood MRD development program aims to validate a non-invasive clinical assay that can regularly measure the presence or absence of MRD and additionally provide a measure of the risk of relapse to guide the use of therapeutics. Telo expects such an assay to lower health care costs and improve patient care outcomes. One of the continuing studies to validate this clinical test is based on a collaboration with the University of Athens which has provided a large cohort of liquid biopsy samples for MRD testing where there are commensurate EuroFlow results to compare.

Provisional patent applications are not examined by the U.S. Patent and Trademark Office, and may not result in issued patents. Any future patent protection, if granted, may be narrower than the application as filed.

About Telo Genomics Corp.

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining the team's considerable expertise in quantitative analysis of 3-D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of its proprietary technology have been substantiated in 160-plus peer-reviewed publications and in 30-plus clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Its lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer.

We seek Safe Harbor.